|
Case HBS Case Collection March 2018 (Revised May 2018) Celgene |
In February 2011, Adam Koppel, a managing director at Brookside Capital, the public equity arm of Bain Capital, must decide whether to increase or exit the firm’s position in Celgene Corporation. News has emerged that raises potential safety concerns associated with Celgene’s key drug, Revlimid. In response, Celgene’s share price has traded down 20% in the last two months and is now almost 10% below the level where Brookside made its initial investment.
Keywords: life sciences; biotechnology; public market investing; Celgene; Revlimid; hedge fund; valuation; growth stocks; Valuation; Investment; Decision Choices and Conditions; Analysis; Biotechnology Industry;
Baker, Malcolm, and Emily McComb. "Celgene." Harvard Business School Case 218-094, March 2018. (Revised May 2018.)
